Profusa Clears Key Hurdle for G3 Deal, Discloses $108M Target Revenue
PFSA sits 40% above its 52-week low of $0.51 on light trading volume (0.2× avg).
Summary
Profusa says it has received G3 Vision Labs' PCAOB-audited FY2024 and FY2025 financials plus reviewed first-half 2026 statements — a core condition to exercising its option to acquire G3. The disclosure puts real numbers on the target for the first time: G3 generated $108 million of FY2025 revenue and $5.0 million of adjusted EBITDA, though it posted a $2.4 million net loss. Profusa has also exchanged $10.7 million of debt and liabilities into a new non-voting convertible preferred series and borrowed $0.7 million in October under its Ascent Partners note to fund near-term working capital. CEO Jack Stover said he believes the company is on track to close by year-end. The scale gap is stark — a micro-cap shell absorbing a nine-figure-revenue lab business — and the preferred converts into common only after stockholder approval, so dilution and the shareholder vote are the gating items. Watch for the stockholder approval and option exercise; Stover targets closing by end of 2026.
At the time of this announcement, PFSA was trading at $0.72 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $333.1K. The 52-week trading range was $0.51 to $1,593.75. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.